Two-thirds of the world’s population under 50 have the highly infectious herpes virus that causes cold sores around the mouth, the World Health Organization said on Wednesday, in its first estimate of global prevalence of the disease. More than 3.7 billion people under the age of 50 suffer from the herpes simplex virus type 1 […]

U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns after initial surgery. The drug, to be sold under the brand name Imlygic, is an engineered version of a herpes virus that kills cancer cells […]

A first-in-class drug from Amgen based on a tumor-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months.   The decision is a further milestone for a technology that has long fascinated scientists but has previously proved difficult to harness. The European […]

Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study. The company’s shares fell 34 percent to $4.75 in premarket trading. Genocea said it was dropping the development of the vaccine, GEN-004, from its near-term plans to […]

The NASDAQ temporarily halted sale of San Diego-based Vical (VICL) stock yesterday in anticipation of news regarding its Phase I/II clinical trial for a genital herpes vaccine. Unfortunately, the trial did not meet either of its primary endpoints and trading resumed with a major drop in share prices. The trial was conducted across seven sites […]